Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AbbVie Rival Boehringer Persuades PTAB To Reexamine Humira Patent

Executive Summary

Like Coherus BioSciences Inc., Boehringer Ingelheim GMBH convinced the US Patent & Trademark Office's Patent Trial and Appeal Board to back the company's inter partes review petition and institute a trial to consider the validity of certain claims on a patent held by AbbVie Inc. on its top-selling drug Humira (adalimumab), which also is facing competition from Amgen Inc., whose biosimilar application is under FDA review and is going before an advisory committee July 12.


Related Content

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Courts, Not FDA Panel, Likely Bigger Hurdle For Amgen's Humira Biosimilar


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts